IL22 and neoplasm: Metformin has also been reported to inhibit primitive CD4+ T cell differentiation into Th1 cells and Th17 cells, thereby reducing IL-22 levels secreted by Th1 cells and Th17 cells, and blocking IL-22-mediated tumor proliferation and anti-apoptotic effects, has an important impact on the occurrence and development of tumors [46].